Since the PI3K/AKT/mTOR pathway negatively regulates autophagy, effective renal cancer cell treatment with mTOR inhibitors (such as TEMS) may thus be antagonized by the resulting increased cellular protective autophagy (7, 8). The gene discussed is MTOR; the disease is renal carcinoma.